Christie CounterAct™ UR10 commercial UVC disinfection products use both UVC-LED and patented Care222® far-UVC light – plus visible white light – within a single fixture for enhanced and safe airborne and surface disinfection in indoor spaces around people.
CounterAct UR10 ceiling-mounted fixtures offer dual protection. Care222 light shines downward to inactivate surface pathogens, and UVC-LED kills airborne pathogens as air circulates across the ceiling. The result? Enhanced, continual disinfection that makes us feel protected, feel normal.
And because CounterAct UR10 fixtures include visible white light, you can simply replace existing commercial lighting anywhere people gather – from corporate offices, workplaces, boardrooms, and lobbies, to retail shopping centers, waiting rooms, classrooms and transit hubs.
We can work with you to determine how many CounterAct UR10 fixtures you need to provide effective coverage of your indoor space. Christie Professional Services offers consultation and installation services to help you add a layer of defense against pathogens in shared indoor spaces.
All references to “disinfect”, “disinfecting”, and “disinfection” refer generally to the reduction of pathogenic bioburden and are not intended to refer to any specific definition as may be used by any governmental or regulatory authority, including the US Food and Drug Administration and the US Environmental Protection Agency. Christie CounterAct products with patented Care222 technology are not medical devices and are not to be used as or for medical devices. The pathogen-reducing efficacy of Christie CounterAct products and their use in occupied spaces is dependent on many site-specific factors as well as proper installation and operation within specifications and in accordance with the American Conference of Governmental Institutional Hygienists (ACGIH) guidelines. Professional installation is recommended for Christie CounterAct products. Ushio’s Care222® filtered Far UV-C technology (“Care222 Technology”) is protected under US and non-U.S. patents covering apparatuses and methods for inactivating viruses or killing bacteria with combinations of a light source and an optical filter that block potentially harmful UV-C wavelengths. Inventions in these patents are credited to Dr. David Brenner, et al., and assigned to Columbia University. Ushio Inc. is the worldwide exclusive licensee of these patents. “Christie” is a trademark of Christie Digital Systems USA, Inc., registered in the United States of America and other countries. This product uses Care222® technology developed by Ushio Inc. The Care222® is a trademark or registered trademark of Ushio Inc. and Ushio America, Inc.
*Tablet not included. App requires Android 5.0 and above or iOS 12.1 and above. Supported tablets include Samsung Galaxy Tab A7/A8/A10 and Apple iPads.